Results 141 to 150 of about 11,142 (157)

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

Lancet, The, 2008
Heikki Hyoty, Mikael Knip, Jorma Ilonen
exaly  

Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial

Lancet, The, 2014
Andrea Barbero, Anna Marsano, Marcel Jakob   +2 more
exaly  

Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers

Lancet, The, 2004
Margreet C Vos, Alex van Belkum, Christina M J E Vandenbroucke-Grauls   +2 more
exaly  

Nasal chondrocyte-based engineered autologous cartilage tissue for repair of articular cartilage defects: an observational first-in-human trial

Lancet, The, 2016
Marcus Mumme, Andrea Barbero, Maria Adelaide Asnaghi   +2 more
exaly  

Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial

Lancet, The, 1999
Crispin Jenkinson
exaly  

Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study

Lancet, The, 2001
Jiri Sonek, Kypros Nicolaides
exaly  

Septoplasty with or without concurrent turbinate surgery versus non-surgical management for nasal obstruction in adults with a deviated septum: a pragmatic, randomised controlled trial

Lancet, The, 2019
Machteld M H T Van Egmond, Maroeska M. Rovers, Gerjon Hannink   +2 more
exaly  

Randomised controlled trial of nasal nicotine spray in smoking cessation

Lancet, The, 1992
Peter Hajek
exaly  

Randomised trial of preventive nasal ventilation in Duchenne muscular dystrophy

Lancet, The, 1994
Sylvie Chevret
exaly  

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Lancet, The, 2019
Claus Bachert, Ludger Klimek, Martin Desrosiers   +2 more
exaly